Sagimet Biosciences Dividends and Buybacks

Dividend criteria checks 0/6

Sagimet Biosciences does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-71.4%

Buyback Yield

Total Shareholder Yield	-71.4%
Future Dividend Yield	0%
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Sagimet: More Than Just A MASH Drug Development Biotech

Nov 14

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat

Oct 18

Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide

Jul 31

Companies Like Sagimet Biosciences (NASDAQ:SGMT) Are In A Position To Invest In Growth

May 31

Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity

Apr 26

Sagimet: Additional Upside Possible After Latest NASH Data Release

Jan 24

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if SGMT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SGMT's dividend payments have been increasing.

Dividend Yield vs Market

Sagimet Biosciences Dividend Yield vs Market

How does SGMT dividend yield compare to the market?
Segment	Dividend Yield
Company (SGMT)	n/a
Market Bottom 25% (US)	1.4%
Market Top 25% (US)	4.2%
Industry Average (Biotechs)	2.3%
Analyst forecast (SGMT) (up to 3 years)	0%

Notable Dividend: Unable to evaluate SGMT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SGMT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate SGMT's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SGMT has not reported any payouts.

Sagimet Biosciences Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Sagimet Biosciences Inc. Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - the Liver Meeting 2024

Sagimet: More Than Just A MASH Drug Development Biotech

Sagimet Biosciences Announces Successful Completion of End-Of-Phase 2 Interactions with Fda on the Development of Denifanstat for Mash

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Sagimet Biosciences Inc. Receives U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for Asc40

Sagimet Biosciences Inc. Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

Sagimet Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Sagimet Biosciences Inc. Announces Appointment of Board of Directors

Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide

Sagimet Biosciences Inc.(NasdaqGM:SGMT) dropped from Russell 3000 Index

Sagimet Biosciences Inc. Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

Companies Like Sagimet Biosciences (NASDAQ:SGMT) Are In A Position To Invest In Growth

Sagimet Biosciences Inc. Announces Appointment of Thierry Chauche as Chief Financial Officer

Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity

Sagimet Biosciences Inc., Annual General Meeting, Jun 05, 2024

Less than half of directors are independent

CEO, President & Director recently bought US$64k worth of stock

Sagimet Biosciences Inc. Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

Sagimet Biosciences Inc. Announces Board Changes

Sagimet Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $112.5 million.

Sagimet Biosciences Inc. has filed a Follow-on Equity Offering.

Sagimet: Additional Upside Possible After Latest NASH Data Release

Sagimet Biosciences Inc. has filed a Follow-on Equity Offering.

Sagimet Biosciences Announces Positive Topline Results from Phase 2B Fascinate-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 Nash

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

New major risk - Share price stability

New minor risk - Market cap size

Sagimet Biosciences Inc. Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

Sagimet Biosciences Inc. Appoints Anthony Rimac as Principal Financial Officer and Principal Accounting Officer, Effective August 1, 2023

Independent Director recently bought US$750k worth of stock

Sagimet Biosciences Inc. has completed an IPO in the amount of $85 million.

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies